Discovery of a promising agonist adjuvant
PVP-037, identified through a small molecule screen, induces a more durable and broader immune response to vaccines.
List view / Grid view
PVP-037, identified through a small molecule screen, induces a more durable and broader immune response to vaccines.
A new assay has been developed which enables the detailing of intact proviral genomes of under-studied HIV strains.
The mouse model provides a new understanding of the fundamental aspects of KSHV, which will enable drug and vaccine development.
In animal studies, the new vaccine construct outperformed another PNAG-vaccine delivery system currently in human trials.
The vaccine provided complete protection with no detectable virus in the lungs and could be a routine part of people’s medical treatment.
This report provides insights into current research and future prospects from potential breakthroughs to global collaboration in pandemic preparedness.
The proof-of-concept study could lead to a cure for HIV that inactivates diverse strains across multiple cellular contexts.
A lab generated monoclonal antibody prevented EBV infection and EBV lymphomas in rodent models and could have future clinical applications.
A new study shows that changes in clonal dominance characterises T-cell memory against multiple COVID-19 variants following mRNA vaccinations.
The study's findings could be applied to the development of new vaccine and therapeutic strategies for influenza.
Researchers found that the D48 antibody neutralised HSV-1 virus infection, which could lead to broad-spectrum drug and vaccine development.
A new vaccine, based on a nanoliposome that promotes proteins to be displayed on its surface, results in potent vaccine efficacy.
As humanity faces an impending era of pandemics, global collaboration among governments, organisations and industry is critical. In this article, epidemiologist Dr Jay Varma explores the urgent need for researching and developing drugs to combat a range of epidemic-prone pathogens, and reflects on the increased risk of spillovers and the…
Researchers have identified key differences between HSV-1 and HSV-2 and have developed monoclonal antibodies that could treat neonatal infections.
Genetic engineering created IgA antibodies that bind to the SARS-CoV-2 spike protein in a similar way to IgG antibodies.